Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Telomir Pharmaceuticals has shared new preclinical findings showing that its Telomir-1 therapy may reactivate tumor suppressor genes MASPIN and RASSF1A. These genes play crucial roles in hindering tumor spread and enhancing chemotherapy response in aggressive prostate cancer models. The abnormal DNA methylation of these genes often leads to their silencing in cancers, reducing natural defense mechanisms. Telomir-1 demonstrated the ability to reverse this process, reactivating these key genes and potentially offering new therapeutic avenues against metastasis and chemotherapy resistance.

The study highlights Telomir-1's potential to reset DNA methylation and revitalize tumor suppressor activity, providing a rationale for its further development. Metastasis and treatment resistance are significant challenges in oncology, and these findings offer hope for a new approach in addressing them. By reactivating natural tumor defenses, Telomir-1 could represent a pivotal shift in epigenetic therapy approaches.